MA46608B1 - Formulation liposomale utile pour le traitement du cancer - Google Patents

Formulation liposomale utile pour le traitement du cancer

Info

Publication number
MA46608B1
MA46608B1 MA46608A MA46608A MA46608B1 MA 46608 B1 MA46608 B1 MA 46608B1 MA 46608 A MA46608 A MA 46608A MA 46608 A MA46608 A MA 46608A MA 46608 B1 MA46608 B1 MA 46608B1
Authority
MA
Morocco
Prior art keywords
compound
cancer
treatment
liposomal formulation
pyrimidin
Prior art date
Application number
MA46608A
Other languages
English (en)
Other versions
MA46608A (fr
Inventor
Peter Wessels
Henricus Tiemessen
Marco Paolo De
Malika Larabi
Christiane Schiedel
Marina Gurina
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of MA46608A publication Critical patent/MA46608A/fr
Publication of MA46608B1 publication Critical patent/MA46608B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne une composition pharmaceutique liposomale comprenant de l'acide 2-{[5-{3-chloro-2-méthyl-4-[2-(4-méthylpipérazin-1-yl)éthoxy]phényl}-6-(4-fluorophényl)thiéno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-méthoxyphényl)pyrimidin-4-yl]méthoxy}phényl) propanoïque, dénommé ici "composé a", ou un sel pharmaceutiquement acceptable de celui-ci. Plus spécifiquement, l'invention concerne un véhicule liposomal, une composition concentrée organique comprenant le composé a, et une composition pharmaceutique pour administration parentérale comprenant des liposomes et le composé a. En outre, l'invention concerne l'utilisation de telles compositions pour le traitement du cancer. Le 'composé a' tel qu'utilisé ici comprend tous les énantiomères, les diastéréoisomères, et les atropisomères de ceux-ci, ou des mélanges de ceux-ci, et également comprend éventuellement les sels pharmaceutiquement acceptables de ceux-ci.
MA46608A 2016-10-28 2017-10-27 Formulation liposomale utile pour le traitement du cancer MA46608B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306415 2016-10-28
PCT/EP2017/077538 WO2018078064A1 (fr) 2016-10-28 2017-10-27 Formulation liposomale destinée à être utilisée dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA46608A MA46608A (fr) 2019-09-04
MA46608B1 true MA46608B1 (fr) 2022-08-31

Family

ID=57288337

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46608A MA46608B1 (fr) 2016-10-28 2017-10-27 Formulation liposomale utile pour le traitement du cancer

Country Status (36)

Country Link
US (1) US10722466B2 (fr)
EP (1) EP3532067B1 (fr)
JP (1) JP7041676B2 (fr)
KR (1) KR102653436B1 (fr)
CN (1) CN109922808B (fr)
AR (1) AR109981A1 (fr)
AU (1) AU2017350499B2 (fr)
BR (1) BR112019008263A2 (fr)
CA (1) CA3041592C (fr)
CO (1) CO2019004190A2 (fr)
CU (1) CU20190046A7 (fr)
CY (1) CY1125446T1 (fr)
DK (1) DK3532067T3 (fr)
EA (1) EA201991025A1 (fr)
ES (1) ES2923929T3 (fr)
GE (1) GEP20217244B (fr)
HR (1) HRP20220952T1 (fr)
HU (1) HUE059448T2 (fr)
IL (1) IL266198B2 (fr)
LT (1) LT3532067T (fr)
MA (1) MA46608B1 (fr)
MD (1) MD3532067T2 (fr)
MX (1) MX391096B (fr)
MY (1) MY194730A (fr)
PH (1) PH12019500804A1 (fr)
PL (1) PL3532067T3 (fr)
PT (1) PT3532067T (fr)
RS (1) RS63400B1 (fr)
RU (1) RU2756755C2 (fr)
SG (1) SG11201903326RA (fr)
SI (1) SI3532067T1 (fr)
TN (1) TN2019000117A1 (fr)
TW (1) TWI749091B (fr)
UA (1) UA126910C2 (fr)
UY (1) UY37459A (fr)
WO (1) WO2018078064A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) * 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
WO2020254299A1 (fr) 2019-06-17 2020-12-24 Les Laboratoires Servier Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers du sein, utilisations et compositions pharmaceutiques associées
WO2022090443A1 (fr) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
EP4312536A1 (fr) 2021-04-01 2024-02-07 Vestaron Corporation Formulations de liposomes destinées à l'administration de pesticides et leurs procédés de production et d'utilisation
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS607932A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソーム懸濁液およびその製法
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20030044454A1 (en) 1998-06-30 2003-03-06 Masaru Fukui Compositions containing liposomes and/or emulsions and process for the preparation thereof
PL203128B1 (pl) * 1999-09-09 2009-08-31 Univ California Liposom zawierający taksan i zastosowanie liposomu kationowego
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
JP2002080400A (ja) 2000-06-23 2002-03-19 Takeda Chem Ind Ltd リン脂質含有薬物の製造法
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
AU2002312777B2 (en) 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EA200501252A1 (ru) 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
JP2005075783A (ja) 2003-09-01 2005-03-24 Otsuka Pharmaceut Factory Inc 難溶性化合物の可溶化または分散化用組成物
JP2005225818A (ja) 2004-02-13 2005-08-25 Otsuka Pharmaceut Factory Inc パクリタキセル又はドセタキセルの医薬組成物
AU2008227852B2 (en) 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
EP2344198B1 (fr) 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Préparations pharmaceutiques à base de lipide(s) à usage topique
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
PT2508170E (pt) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
JP2012051823A (ja) 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
BR112013014291A2 (pt) 2010-12-08 2016-09-20 Hoffmann La Roche formulação lipossômica de calcetrapib
US20130337051A1 (en) 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
CN103622911B (zh) 2013-11-19 2015-12-30 常州金远药业制造有限公司 一种难溶性药物脂质体制备方法
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HRP20220952T1 (hr) 2022-10-28
HUE059448T2 (hu) 2022-11-28
IL266198B1 (en) 2023-07-01
RS63400B1 (sr) 2022-08-31
UA126910C2 (uk) 2023-02-22
UY37459A (es) 2018-05-31
DK3532067T3 (da) 2022-07-25
SG11201903326RA (en) 2019-05-30
KR20190076004A (ko) 2019-07-01
TN2019000117A1 (en) 2020-10-05
PL3532067T3 (pl) 2022-08-16
KR102653436B1 (ko) 2024-03-29
LT3532067T (lt) 2022-08-25
JP7041676B2 (ja) 2022-03-24
CO2019004190A2 (es) 2019-07-10
MD3532067T2 (ro) 2022-10-31
AU2017350499B2 (en) 2023-08-10
BR112019008263A2 (pt) 2019-07-09
AU2017350499A1 (en) 2019-05-09
TWI749091B (zh) 2021-12-11
IL266198A (en) 2019-06-30
CN109922808B (zh) 2023-02-03
IL266198B2 (en) 2023-11-01
EP3532067B1 (fr) 2022-05-04
CU20190046A7 (es) 2019-12-03
ES2923929T3 (es) 2022-10-03
EP3532067A1 (fr) 2019-09-04
TW201818942A (zh) 2018-06-01
CY1125446T1 (el) 2025-05-09
SI3532067T1 (sl) 2022-09-30
JP2019532973A (ja) 2019-11-14
MX2019004941A (es) 2019-06-24
MA46608A (fr) 2019-09-04
AR109981A1 (es) 2019-02-13
US20200054557A1 (en) 2020-02-20
GEP20217244B (en) 2021-04-26
PH12019500804A1 (en) 2020-01-20
MX391096B (es) 2025-03-21
RU2756755C2 (ru) 2021-10-05
PT3532067T (pt) 2022-07-04
CN109922808A (zh) 2019-06-21
RU2019115688A (ru) 2020-11-30
WO2018078064A1 (fr) 2018-05-03
MY194730A (en) 2022-12-15
RU2019115688A3 (fr) 2021-01-13
CA3041592C (fr) 2023-01-17
CA3041592A1 (fr) 2018-05-03
US10722466B2 (en) 2020-07-28
EA201991025A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
PH12019500804A1 (en) Liposomal formulation for use in the treatment of cancer
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2019246349A8 (fr) Composés antagonistes du pcsk9
TN2016000227A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides.
MA37405A1 (fr) Composés hétérocyclyle
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2019143902A3 (fr) Hétérocycles substitués utiles en tant qu'agents antiviraux
WO2017123884A8 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
MX2020001403A (es) Nuevos derivados de quinolina.
MX347544B (es) Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
WO2006067614A3 (fr) Derives heteroaromatiques utiles en tant qu'agents anticancereux
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JP2015501833A5 (fr)
EP3693369A3 (fr) Inhibiteurs de bromodomaine
WO2014031438A3 (fr) Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
AU2020231934A8 (en) Compounds useful in HIV therapy
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide